Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH

Survodutide's effect on resolving or improving MASH was largely mediated by weight reduction, but its effect on fibrosis and inflammation/fibrosis-related markers was largely weight-independent. This post hoc mediation analysis of 170 phase 2 MASH participants suggests that survodutide may have direct liver effects beyond weight loss.

Journal article — Post hoc mediation analysis of phase 2 trial. Population: Participants with MASH and fibrosis stage F2-F3 who had paired baseline and end-of-treatment biopsy readings. Sample size: 170 participants. Follow-up: 48 weeks' treatment. Interventions: Survodutide.

A total of 170 participants were included. For histological endpoints, the proportion of the total survodutide effect mediated by weight reduction was 66.7% for MASH resolution without fibrosis worsening, 71.8% for MASH improvement without fibrosis worsening, and 36.3% for fibrosis improvement without MASH worsening. For inflammation/fibrosis-related non-invasive tests, the weight-mediated proportion was 16.5% for AST and 38.6% for Enhanced Liver Fibrosis. For steatosis-related endpoints, it was 58.2% for MRI-proton density fat fraction and 77.4% for FibroScan Controlled Attenuation Parameter. The authors concluded that inflammation/fibrosis improvements were predominantly weight-reduction-independent, suggesting a possible direct hepatic effect of glucagon receptor agonism.

For researchers studying survodutide, this paper helps separate weight-loss-mediated effects from potential direct hepatic effects, which is important for interpreting MASH trial endpoints. It does not establish a definitive molecular mechanism or prove that glucagon receptor agonism acts directly in the liver, and it does not support clinical decisions by itself.

Key findings

• Weight reduction mediated 66.7% of the total effect on resolution of MASH without worsening of fibrosis.
• Weight reduction mediated 71.8% of the effect on improvement in MASH without worsening of fibrosis, but only 36.3% of the effect on improvement in fibrosis without worsening of MASH.
• For inflammation/fibrosis-related non-invasive tests, less than 50% of the total effect was mediated by weight reduction: 16.5% for AST and 38.6% for Enhanced Liver Fibrosis.
• For steatosis-related endpoints, weight reduction mediated 58.2% of the effect on MRI-proton density fat fraction and 77.4% of the effect on FibroScan Controlled Attenuation Parameter.
• The analysis included 170 participants with fibrosis stage F2-F3 and paired baseline/end-of-treatment biopsies.

Limitations

• Post hoc analysis of a phase 2 trial
• Survodutide dose arms were pooled, so dose-response relationships were not assessed
• Causal mediation analysis relies on assumptions about unmeasured confounding
• Findings are limited to F2-F3 MASH and surrogate liver endpoints, not clinical outcomes

The record

• Journal: Hepatology (Baltimore, Md.)
• Published: 2026-08-03
• PMID: 42545725 — DOI: 10.1097/hep.0000000000001825
• Author countries: France, Germany, Italy, UK, USA

Peptide profiles: Survodutide.

All indexed evidence: Survodutide trials & papers.

Related studies: Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell…, Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver…, Survodutide Once Weekly for the Treatment of Adults with Obesity, Author Correction: Survodutide in adults with obesity and metabolic….